Cove Street Capital’s Trinity Biotech TRIB Stock Holding History

Cove Street Capital’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-18,380	Closed	-$473K	–	108
2018 Q1	$473K	Hold	18,380	–	–	0.05%	89
2017 Q4	$469K	Hold	18,380	–	–	0.05%	91
2017 Q3	$516K	Sell	18,380 -21,620	-54%	-$603K	0.06%	90
2017 Q2	$1.2M	Hold	40,000	–	–	0.15%	71
2017 Q1	$1.19M	Hold	40,000	–	–	0.13%	68
2016 Q4	$1.38M	Buy	+40,000	New	+$1.38M	0.14%	68

Other funds holding TRIB

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

Cove Street Capital's TRIB Position: Q2 2018 in Review

Cove Street Capital sold out of Trinity Biotech (TRIB) in Q2 2018, closing a stake of 18,380 shares — an estimated $473K sold.

Cove Street Capital first reported a position in TRIB in Q4 2016 and held it in 6 quarters. The position peaked at $1.38M in Q4 2016. 45 funds tracked by Wall St. Rank hold TRIB as of Q2 2018.

Cove Street Capital reported no remaining Trinity Biotech position as of Q2 2018 after selling out during the quarter.
Cove Street Capital sold 18,380 Trinity Biotech shares in Q2 2018, an estimated $473K.
Cove Street Capital first reported a position in Trinity Biotech in Q4 2016 and held it in 6 quarters.
Cove Street Capital's Trinity Biotech position peaked at $1.38M in Q4 2016.
45 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2018.

Based on Cove Street Capital's 13F filing for Q2 2018, filed 13 Aug 2018.